Duracyte’s implants employ cells engineered to produce therapeutic protein, bypassing the complexities of traditional biologics manufacturing. The startup’s marriage of biotechnology with electronics comes with on-board sensors that enable clinicians to monitor and control an implant’s drug production process. The post This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’ appeared first on MedCity News.

View Entire Post